Mizuho analyst Salim Syed upgraded Incyte (INCY) to Outperform from Neutral with a price target of $121, up from $90. The firm has higher confidence in the company’s pipeline following the “promising” myelofibrosis Phase 1 data. Mizuho now sees potential for Incyte’s pipeline to “soften” the Jakafi loss of exclusivity in 2028 and provide growth from 2030 onward.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY: